Protein A Chromatography Resin Patents: Leaders & White Space 2026
- Filing has grown +11% from 2021 to 2024, the last year the dataset treats as complete, with 2024 the peak filing year so far at 10 records.
- One assignee leads with 12 records while the ranked field falls away quickly to a long tail of individual inventors and academic filers holding single digits down to one record each.
- Every record in scope sits in C07K (peptides and proteins), but only about a third also touch B01D separation processes — a gap between binding chemistry claims and the hardware built around them.
Filing growth compares 2021 (9 records) with 2024 (10) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
Protein A affinity chromatography resin is the workhorse capture step for monoclonal antibody purification, and the patent activity tracked here concentrates on the properties that decide whether a resin survives commercial-scale use: dynamic binding capacity, alkaline stability under cleaning-in-place cycles, ligand leaching, and cycle lifetime. These are the parameters process engineers actually specify when qualifying a resin, and they map closely onto where applicants have chosen to stake claims.
The scope here is a focused 26-record set spanning 2015 through mid-2026, not the entire chromatography resin field. It is small enough that single filings move the picture, and recent-year counts understate real activity because publication lags filing by roughly eighteen months.
Filing trend and technology composition
Two views of the same 26-record set: how filing volume has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017-2026
Filings rose from zero in 2017 to a peak of 10 in 2024, with growth of +11% measured from 2021 (9 records) to 2024 (10 records). 2025 and 2026 counts are still filling in as publications catch up with filings, so they should not be read as a slowdown.
IPC subclass distribution
All 26 records carry a C07K peptide/protein classification, 34.6% also carry B01D separation-process classes, and smaller shares extend into A61K medicinal preparations, B01J catalysis, B82Y nanotechnology and D01D filament spinning. Because records can carry multiple classes, these shares add up to more than 100% of the 26 records in scope.
Shares are the percentage of the 26 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Protein A Affinity Chromatography Resins with Eureka
This page is one run against one query. Ask Eureka your own question about protein a affinity chromatography resins and every answer comes back with the patent numbers behind it.
Try EurekaA recent claim shaping the field
Fusion protein for affinity capture (AU2024362144A1)
The application describes a fusion protein combining a single-chain binding polypeptide with a separate stabilizing polypeptide built around an alpha-helix-containing domain that itself has no binding affinity for the target. The stabilizer is claimed to improve properties of the binding moiety alone, including alkaline stability, over the binding domain used without it.Filed by Cytiva Bioprocess R&D AB, published 2026-04-09.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2009135656A1 | A method for the purification of antibodies using displacement chromatography | 65 |
| 2 | WO2025083263A1 | Fusion protein for affinity capture | 2 |
| 3 | WO2022129460A1 | Methods for the purification of refolded fc-peptide fusion protein | 2 |
| 4 | WO2025083267A1 | AAV9 binding polypeptides | 1 |
| 5 | EP4088812A1 | Cartridge for use in chromatography | 1 |
Citation counts favour older publications simply because they have had longer to accumulate citations inside this corpus; treat them as a signal of influence, not of present-day importance.
Publication numbers are shown where the record carries one (5 of 5 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three patterns worth weighing before drafting claims or scoping freedom-to-operate in this space.
Growth is real but modest, not explosive
The three-year climb from 9 to 10 records is steady rather than a land grab. A resin developer entering now is not racing a wave of new filings; the field has been adding claims gradually rather than surging.
One leader, then a steep drop to single filers
The ranked leader holds 12 records against a tenth-place assignee holding just one. That gap suggests most of the ranked field are academic groups or individual inventors testing narrow claims rather than building portfolios.
Binding chemistry is claimed far more than hardware
Every record touches peptide and protein chemistry under C07K, but only about a third extend into B01D separation-process claims covering columns, cartridges or flow formats. Ligand and resin-surface chemistry is the crowded ground; the physical format around it is comparatively open.
Recent activity has shifted assignee
Several previously active academic filers show zero filings in the latest year with -100% year-on-year change, while the top-ranked commercial assignee logged 2 records in that same window. Momentum has moved toward industry filers even as the overall count stays small.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to protein a affinity chromatography resins, with the prior art for and against each one.
Assignee landscape
The ranked field covers 10 companies as returned by the dataset, led by one commercial assignee at 12 records ahead of a long tail that includes academic institutions and named inventors filing individually.
A single commercial filer dominates the ranking
The top-ranked assignee holds 12 of the records in the ranking, well clear of the rest of the field, and is also the only assignee showing filings in the latest year.
One research institution anchors a co-filing cluster
A single academic institution appears paired with three different named inventors, each pairing occurring twice, pointing to a lab group filing collaboratively rather than a single principal investigator working alone.
Individual inventors hold the bottom of the ranking
The tenth-ranked assignee holds just one record, and several named individuals rather than corporations appear in the ranked list, consistent with a field still open to narrow, defensible claims from smaller filers.
| Assignee | Recent year | YoY |
|---|---|---|
| Cytiva Bioprocess R&D AB | 2 | — |
| Jiri Factory | 0 | — |
| Rensselaer Polytechnic Institute | 0 | -100% |
| NEUMAN THOMAS | 0 | -100% |
| KARANDE PANKAJ | 0 | -100% |
| HU MENGYANG | 0 | -100% |
| BELFORT GEORGES | 0 | -100% |
| Lonza Biologics plc | 0 | — |
Where to take this analysis
The dataset points to a field with concentrated binding-chemistry claims and comparatively open hardware and format space.
Map freedom-to-operate against the leader's 12 records
Before drafting new ligand or stability claims, check overlap with the top-ranked assignee's portfolio specifically, since it is the only filer showing sustained activity into the latest year.
Explore assignee portfolios in EurekaScope claims toward the B01D and B82Y gap
Format and hardware classes remain thin relative to the C07K core, suggesting room for claims on cartridge, flow, or nanoparticle-supported resin formats that pair with existing binding chemistry.
Run a white-space search in EurekaQuestions practitioners ask
Within this 26-record dataset, one assignee leads with 12 records, well ahead of the rest of the ranked field of 10 companies. The remaining assignees fall away quickly, with the tenth-ranked holder at just one record. This concentration at the top, alongside a long tail of academic and individual filers, suggests the leading commercial player has built the most defensible position in binding-ligand chemistry, while smaller filers are staking narrower, more specific claims.
Filing grew +11% from 2021 (9 records) to 2024 (10 records), the most recent year this dataset treats as complete. Counts for 2025 and 2026 appear lower, but that reflects publication lag of roughly eighteen months rather than an actual drop in filing. Based on the complete years available, the trend is one of steady, modest growth rather than acceleration or decline.
Every record in this dataset carries a C07K classification, covering peptide and protein chemistry, which is the core of ligand and binding-domain claims. About a third of records also carry a B01D separation-process classification covering chromatography hardware and flow formats. Smaller shares touch medicinal preparations, catalysis, nanotechnology, and filament-based media, which points to binding chemistry as the most crowded ground and hardware format as comparatively open.
AU2024362144A1, filed by Cytiva Bioprocess R&D AB and published 2026-04-09, claims a fusion protein pairing a single-chain binding polypeptide with a separate stabilizing polypeptide built around an alpha-helix domain that itself does not bind the target. The claimed benefit is improved alkaline stability and related properties compared to the binding domain alone. For anyone designing a Protein A-based ligand meant to survive alkaline cleaning cycles, this filing is a relevant reference point for how stabilizing domains are being claimed separately from the binding function itself.
The clearest gap in this dataset sits between binding chemistry, claimed in all 26 records, and physical resin format, claimed in only about a third of records under B01D, with smaller pockets in B82Y nanotechnology and D01D filament spinning. That gap suggests opportunity in claims that pair known alkaline-stable ligand chemistry with less-claimed formats such as nanoparticle-supported matrices, spun-fiber capture media, or specific cartridge and flow-path hardware, rather than in the ligand chemistry itself, which is already densely claimed by the leading assignee.
Research Protein A Affinity Chromatography Resins in depth with Eureka
Go past this page: query the whole protein a affinity chromatography resins corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.